DMA Diamedica Therapeutics

DiaMedica Inc. (TSX VENTURE:DMA), a drug discovery and clinical development
company focused on a novel approach to treating type 2 diabetes, today announced
that Rick Pauls, President and Chief Executive Officer, will participate in two
upcoming investor forums. The forums, with select attendees drawn from leading
institutional investors and pharmaceutical industry representatives, will be
held from Sunday, January 25th through Thursday, January 30th in Boston and New
York City.


We are delighted to be presenting DiaMedica to US investors at this innovative
showcase," said Mr. Pauls. "This is an ideal forum to update investors and
potential partners on the positive clinical data we have achieved to date as
well as the on-going DM-99 trial and planned clinical trials that will be
initiated in the near future."


The investment meetings have been organized by the Canadian Consulate Generals
Office from each respective city, in cooperation with the Ottawa Centre for
Research and Innovation (OCRI), in order to promote Canada's most promising life
science companies to the US investment community. Future investment forums are
scheduled for Washington DC, San Francisco and San Diego.


Diabetes is a widespread and rapidly growing disease, affecting over 180 million
people world wide. Over 90% of people with diabetes are being diagnosed with the
type 2 form of the disease. According to the World Health Organization, this
number is expected to double during the next 15 years while the American
Diabetes Association has estimated the annual economic cost in 2007 to the
United States to be $174 billion. Global sales of oral diabetes drugs total $8
billion today and are expected to climb to $12 billion by 2011.


About DiaMedica

DiaMedica is developing novel treatments for type 2 diabetes based on a newly
discovered 'nerve reflex' mechanism for which the Company has been issued two
U.S. patents. DiaMedica completed a successful phase II trial with its lead
product, DM-71, which demonstrated the ability to reduce HbA1c (blood sugar)
levels and weight in humans. DiaMedica also completed a successful phase II
trial with its second compound, DM-83, designed to measure changes in insulin
and glucose. The success of this clinical trial was highly significant as
DiaMedica believes it validates the novel 'nerve reflex' mechanism that would
designate the Company's drugs as first-in-class. The Company's third drug in
clinical development, DM-99, will complete a phase II trial in Q1 2009.
Preclinical results from Vanderbilt University have shown that DM-99 is able to
cause tissue to increase its uptake of sugar from the blood by over 40% (p less
than 0.001) during the first 60 minutes of treatment. DM-199, a 40x more
biologically active version of DM-99, has been created with the expectation that
it will be developed into a once-a-week injection. DiaMedica has been recognized
as one of the Top Ten(TM) Life Science companies in Canada for the past two
years by the Ottawa Centre for Research and Innovation.


Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking
information within the meaning of applicable Canadian provincial securities
legislation (collectively, "forward-looking statements"). These forward-looking
statements relate to, among other things, our objectives, goals, targets,
strategies, intentions, plans, beliefs, estimates and outlook, including,
without limitation, our anticipated future operating results, and can, in some
cases, be identified by the use of words such as "believe," "anticipate,"
"expect," "intend," "plan," "will," "may" and other similar expressions. In
addition, any statements that refer to expectations, projections or other
characterizations of future events or circumstances are forward-looking
statements.


These statements reflect management's current beliefs and are based on
information currently available to management. Certain material factors or
assumptions are applied in making forward-looking statements, and actual results
may differ materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ materially from
these expectations include, among other things: DiaMedica's early stage of
development, lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development, rapid
technological change, uncertainties related to forecasts, competition, potential
product liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters, management of
growth, partnerships for development and commercialization of technology,
effects of insurers' willingness to pay for products, system failures,
dependence on key personnel, foreign currency risk, risks related to regulatory
matters and risks related to intellectual property and other risks detailed from
time to time in DiaMedica's filings with Canadian securities regulatory
authorities, as well as DiaMedica's ability to anticipate and manage the risks
associated with the foregoing. Additional information about these factors and
about the material factors or assumptions underlying such forward-looking
statements may be found in the body of this news release, as well as under the
heading "Risk Factors" contained in DiaMedica's final long-form prospectus dated
March 12, 2007. DiaMedica cautions that the foregoing list of important factors
that may affect future results is not exhaustive. When relying on DiaMedica's
forward-looking statements to make decisions with respect to DiaMedica,
investors and others should carefully consider the foregoing factors and other
uncertainties and potential events.


These risks and uncertainties should be considered carefully and prospective
investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in this press release are
based upon what management believes to be reasonable assumptions, DiaMedica
cannot provide assurance that actual results will be consistent with these
forward-looking statements. DiaMedica undertakes no obligation to update or
revise any forward-looking statement.

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024